Panda et al. (2012) demonstrated the tumor-suppressive potential of MIR98 via targeting of CYP19A1 mRNA, which demonstrated reduced estrogen levels in 52 patients compared to 15 healthy individuals. The gene discussed is MIR98; the disease is neoplasm.